Efficacy and Safety of Mirikizumab (LY3074828) in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Randomised Phase 2 Study.

CONCLUSIONS: At Week 16, 66.7% of patients treated with mirikizumab 300 mg at 8-week intervals achieved PASI 90. The percentage of patients reporting at least one treatment-emergent adverse event was similar among patients treated with placebo or mirikizumab. This article is protected by copyright. All rights reserved. PMID: 30734266 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30734266?dopt=Abstract

Source: The British Journal of Dermatology - February 7, 2019 Category: Dermatology Authors: Reich K, Rich P, Maari C, Bissonnette R, Leonardi C, Menter A, Igarashi A, Klekotka P, Patel D, Li J, Tuttle J, Morgan-Cox M, Edson-Heredia E, Friedrich S, Papp K, AMAF investigators Tags: Br J Dermatol Source Type: research